We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medarex Announces NovImmune Filing of IND Application for Fully Human Antibody
News

Medarex Announces NovImmune Filing of IND Application for Fully Human Antibody

Medarex Announces NovImmune Filing of IND Application for Fully Human Antibody
News

Medarex Announces NovImmune Filing of IND Application for Fully Human Antibody

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medarex Announces NovImmune Filing of IND Application for Fully Human Antibody"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medarex, Inc. has announced the filing of an Investigational New Drug (IND) application in the Netherlands by its licensing partner, NovImmune SA, for NI- 0401, a fully human antibody that targets the CD3 antigen, for the treatment of autoimmune disease.

The antibody product was developed using Medarex's UltiMAb® technology.

Medarex expects to receive an undisclosed milestone payment and may receive future milestone payments and royalties should this product candidate progress through clinical development.

"We are pleased with the progress that our partner, NovImmune, has achieved in filing an IND," said Donald L. Drakeman, President and CEO of Medarex, Inc.

"With the advancement of the NovImmune antibody into clinical trials, there are now twenty-nine fully human antibodies generated from Medarex's technology that are in clinical development by Medarex and its partners."

Advertisement